KDR and neoplasm: For example, PI3K/mTOR, PI3K/HDAC, PI3K/AKT/mTOR, and PDGFR/PI3K/EGFR/VEGFR2 multi-target inhibitors were developed with the hope of effectively improving anti-tumour activity.